AS1708727 is an orally active Foxo1 inhibitor, with EC 50 values of 0.33 μM and 0.59 μM for G6Pase and PEPCK, respectively.
性状
Solid
体外研究(In Vitro)
AS1708727 suppresses increases in blood glucose level by inhibiting gluconeogenic gene expression. has not independently confirmed the accuracy of these methods. They are for reference only.RT-PCR
体内研究(In Vivo)
AS1708727 (30 to 300 mg/kg, orally) reduces both blood glucose and triglyceride levels, exhibiting anti-diabetic effects. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: db/db
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Hirotsugu Tanaka, et al. Effects of the Novel Foxo1 Inhibitor AS1708727 on Plasma Glucose and Triglyceride Levels in Diabetic Db/Db Mice. Eur J Pharmacol. 2010 Oct 25;645(1-3):185-91.
溶解度数据
In Vitro: DMSO : 41.67 mg/mL (93.98 mM; Need ultrasonic)配制储备液
[1]. Hirotsugu Tanaka, et al. Effects of the Novel Foxo1 Inhibitor AS1708727 on Plasma Glucose and Triglyceride Levels in Diabetic Db/Db Mice. Eur J Pharmacol. 2010 Oct 25;645(1-3):185-91.